SCHEMBL3135567

SCHEMBL3135567

N#Cc1ccc2c(ccn2CC2CC2)c1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NPY5R Q15761 1/20 0.47
KDM1A O60341 9/20 0.46
GRM2 Q14416 1/20 0.46
P2RX7 Q99572 1/20 0.46
PRMT5 O14744 1/20 0.46
KDM4E B2RXH2 2/20 0.45
ALDH1A1 P00352 2/20 0.45
TSHR P16473 2/20 0.45
HSD17B10 Q99714 2/20 0.45
USP2 O75604 1/20 0.45
POLB P06746 1/20 0.45
HPGD P15428 1/20 0.45
KDM2B Q8NHM5 1/20 0.42
CNR1 P21554 1/20 0.41
CNR2 P34972 1/20 0.41
SIGMAR1 Q99720 1/20 0.40
CDC7 O00311 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22439463 0.90 CNR2 (0.52) NPY5RKDM1AGRM2P2RX7PRMT5
SCHEMBL6998824 0.86 KDM1A (0.59) KDM1A
Hydrochloric Acid SCHEMBL7951984 0.85 KDM1A (0.58) KDM1A
SCHEMBL18003252 0.84 ALDH1A1 (0.56) KDM1APRMT5KDM4EALDH1A1TSHR
SCHEMBL18003080 0.82 ALDH1A1 (0.61) KDM1APRMT5KDM4EALDH1A1TSHR
SCHEMBL3921573 0.82 P2RX7 (0.46) NPY5RKDM1AGRM2P2RX7PRMT5
SCHEMBL4824315 0.81 KDM1A (0.54) KDM1AKDM4EALDH1A1TSHRHSD17B10
SCHEMBL17079057 0.79 KDM1A (0.47) KDM1A
SCHEMBL31200491 0.79 ALDH1A1 (0.55) NPY5RKDM1APRMT5KDM4EALDH1A1
SCHEMBL6991633 0.79 P2RX7 (0.47) P2RX7PRMT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2125683-B1 3-BENZOFURANYL-4-INDOLYL-MALEIMIDES AS POTENT GSK-3 INHIBITORS FOR NEURODEGENERATIVE DISORDERS UNIV ILLINOIS (US) 2013-10-23 EP disclosed
US-8207216-B2 Benzofuran-3-yl(indol-3-yl) maleimides as potent GSK3 inhibitors THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2012-06-26 US disclosed
US-20100004308-A1 Benzofuran-3-yl(indol-3-yl) Maleimides as Potent GSK3 Inhibitors THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, A BODY CORPORATE AND POLITIC OF THE STATE OF ILLINOIS 2010-01-07 US disclosed
EP-2125683-A1 3-BENZOFURANYL-4-INDOLYL MALEIMIDES AS POTENT GSK3 INHIBITORS FOR NEUROGENERATIVE DISORDERS The Board of Trustees of the University of Illinois (US) 2009-12-02 EP disclosed
WO-2008077138-A1 3-BENZOFURANYL-4-INDOLYL MALEIMIDES AS POTENT GSK3 INHIBITORS FOR NEUROGENERATIVE DISORDERS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2008-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004308-A1 Benzofuran-3-yl(indol-3-yl) Maleimides as Potent GSK3 Inhibitors GSK3B, GSK3A, GSKIP NPY5R 1649/4885KDM1A 2752/4885GRM2 1323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.